Patents Assigned to AstraZeneca
  • Patent number: 7442697
    Abstract: Compounds of the formula (I): wherein R1, R2, R3, R4, R5 and p are as defined within and a pharmaceutically acceptable salts and in vivo hydrolysable esters are described. Also described are processes for their preparation and their use as medicaments, particularly medicaments for producing a cell cycle inhibitory (anti-cell-proliferation) effect in a warm-blooded animal, such as man.
    Type: Grant
    Filed: March 6, 2003
    Date of Patent: October 28, 2008
    Assignee: AstraZeneca AB
    Inventors: Nicholas John Newcombe, Andrew Peter Thomas
  • Patent number: 7442704
    Abstract: The invention concerns amide derivatives of Formula (Ia) wherein X is —NHCO— or —CONH—; m is 0-3; R1 is a group such as hydroxy, halogeno, trifluoromethyl, cyano, mercapto, nitro, amino, carboxy and carbamoyl; n is 0-2; R2 is a group such as hydroxy, halogeno, trifluoromethyl, cyano, mercapto, nitro, amino and carboxy; R3 is hydrogen, halogeno, (1-6C)alkyl or (1-6C)alkoxy; q is 0-4; and Q is a group such as aryl, aryloxy, aryl-(1-6C)alkoxy, arylamino and N-(1-6C)alkyl-arylamino; or pharmaceutically-acceptable salts or in-vivo-cleavable esters thereof; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases or medical conditions mediated by cytokines.
    Type: Grant
    Filed: July 8, 2005
    Date of Patent: October 28, 2008
    Assignee: AstraZeneca AB
    Inventor: Dearg S Brown
  • Patent number: 7442811
    Abstract: Process for the preparation of an ester of formula (1), wherein R1 represents a leaving group, CN, OH or a COOR5 group, R3 and R4 each independently represent a 1-3 C alkyl group, and R2 and R5 each independently represent an ester residue, wherein the corresponding salt with formula (2), wherein M represents H or an alkali (earth) metal in an inert solvent is contacted with an acid chloride forming agent to form the corresponding acid chloride, and the acid chloride is contacted with an alcohol with formula R2OH in the presence of N-methyl-morpholine. Preferably M represents an alkali metal, and R2 represents an alkyl group, particularly a t.-butyl group.
    Type: Grant
    Filed: June 12, 2003
    Date of Patent: October 28, 2008
    Assignee: AstraZeneca UK Limited
    Inventors: Hermanus Carolus Catherina Karel Bakel Van, Dominique Monique Charles Callant, Jacob Hermanus Mattheus Hero Kooistra, Peter Johannes Dominicus Maas
  • Publication number: 20080262038
    Abstract: Compounds of Formula: wherein R1, R2, and R3 are as defined in the specification, as well as salts, enantiomers thereof and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.
    Type: Application
    Filed: January 5, 2005
    Publication date: October 23, 2008
    Applicant: ASTRAZENECA AB
    Inventors: William Brown, Andrew Griffin, Christopher Walpole
  • Publication number: 20080262026
    Abstract: Certain 4,5,6,7-tetrahydropyrrolo[3,2-c]pyridin-4-one and 4,5-dihydropyrrolo[3,2-c]pyridin-4-one compounds of formula I, processes for preparing such compounds, their use in the treatment of obesity, psychiatric and neurological disorders, methods for their therapeutic use and pharmaceutical compositions containing them are described.
    Type: Application
    Filed: April 3, 2008
    Publication date: October 23, 2008
    Applicant: AstraZeneca AB
    Inventors: Leifeng CHENG, Sara Annelie HELGESSON
  • Publication number: 20080262229
    Abstract: Compounds of formula: wherein R1 and R2 are as defined in the specification, as well as salts, enantiomers thereof and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.
    Type: Application
    Filed: February 24, 2006
    Publication date: October 23, 2008
    Applicant: ASTRAZENECA AB
    Inventors: William Brown, Andrew Griffin, Andrea Penwell
  • Publication number: 20080262811
    Abstract: The present invention relates crystals of LigA and computer-assisted methods for screening, identifying, and designing inhibitors and allosteric modulators of LigA.
    Type: Application
    Filed: August 9, 2005
    Publication date: October 23, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Sushmita Lahiri, Scott Mills
  • Publication number: 20080262064
    Abstract: The present invention relates to novel imidazole compounds having a positive allosteric GABAB receptor (CUR) modulator effect, methods for the preparation of said compounds and to their use, optionally in combination with a GABAB agonist, for the inhibition of transient lower esophageal sphincter relaxations, for the treatment of gastroesophageal reflux disease, as well as for the treatment of functional gastrointestinal disorders and irritable bowel syndrome (IBS).
    Type: Application
    Filed: April 17, 2008
    Publication date: October 23, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Udo Bauer, Wayne Brailsford, Leifeng Cheng, Maria Jonforsen, Florian Raubacher, Peter Schell, Tor Svensson
  • Publication number: 20080262882
    Abstract: Methods and systems for providing and correlating clinical and business performance measures and benchmarks for medical practitioners are provided. Clinical and business data is collected from a plurality of medical practitioners. The clinical data may pertain to one or more clinical metrics that relate to treatment offered to patients by medical practitioners. The business data may pertain to one or more business metrics that relate to commercial performance of the medical practitioners. Several benchmarking reports are prepared based on this data and provided to different medical practitioners showing them where they stand in comparison to other practitioners within their practice, specific or general discipline or industry.
    Type: Application
    Filed: April 18, 2007
    Publication date: October 23, 2008
    Applicant: AstraZeneca AB
    Inventor: Aidan Farrell
  • Publication number: 20080262037
    Abstract: The present invention provides a compound of a formula (I) wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a chemokine (such as CCR3) or H1 mediated disease state.
    Type: Application
    Filed: April 5, 2005
    Publication date: October 23, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Tobias Mochel, Matthew Perry, Brian Springthorpe
  • Publication number: 20080261910
    Abstract: The present invention arises from the identification of an association between the gene encoding glucosyltransferase-like protein (GT) and osteoarthritis (OA). It therefore relates to diagnostic techniques for determining a patient's susceptibility to develop OA by detecting all or part of the GT gene, its precursors or products (mRNA, cDNA, genomic DNA, or protein). In particular, the invention relates to methods and materials for analysing allelic variation in the GT gene, and to the use of GT polymorphisms in the identification of an individuals' risk to develop OA. The invention is also directed to methods for identifying modulators of OA, which modulate the GT gene or its encoded protein.
    Type: Application
    Filed: September 20, 2006
    Publication date: October 23, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Angela Flannery, Rose Maciewicz
  • Publication number: 20080261240
    Abstract: A method for attenuating a microorganism which comprises inhibiting in the microorganism a metabolic pathway essential for viability, by promoting use of the substrate of the pathway in a different metabolic pathway which is non-essential to the microorganism whereby the substrate is unavailable to the essential pathway and the micro organism is attenuated.
    Type: Application
    Filed: April 21, 2008
    Publication date: October 23, 2008
    Applicant: ASTRAZENECA AB
    Inventors: SoundaRajan Tanjore Balganesh, Santanu Datta, Indira Ghosh
  • Patent number: 7439356
    Abstract: The present invention relates to intermediates of the formula useful in the preparation of piperazinyl-substituted indan derivatives, wherein Y is CONR2 wherein R2 is H or C1-C6 alkyl; R3 is C1-C6 alkyl, C3-C6 cycloalkyl or (CH2)n-aryl, wherein aryl is phenyl or a heteroaromatic ring containing one or two heteroatoms selected from N, O and S and which may be mono- or di-substituted with R4 and/or R5, wherein R4 and R5 are as defined in the specification; and R9 is H, C1-C6 alkyl, C3-C6 cycloalkyl, OCF3, OCHF2, OCH2F, halogen, CN, CF3, OH, C1-C6 alkoxy, C1-C6 alkoxy-C1-C6 alkyl, NR6R7, SO3CH3, SO3CF3, SO2NR6R7, an unsubstituted or substituted heterocyclic or heteroaromatic ring containing one or two heteroatoms selected from N and O, wherein the substituent(s) is(are) C1-C6 alkyl; or COR8; wherein R6, R7 and R8 are as defined in the specification. The invention further relates to a process for the preparation of the intermediates.
    Type: Grant
    Filed: October 3, 2006
    Date of Patent: October 21, 2008
    Assignee: AstraZeneca AB
    Inventors: Stefan Berg, Lennart Florvall, Svante Ross, Seth-Olov Thorberg
  • Patent number: 7439355
    Abstract: There is provided a process for the preparation of a compound of formula I, (I), or a pharmaceutically acceptable derivative thereof, wherein A, B, G, R1, R2, R3, R4 and R41 to R46 have meanings given in the description, which process comprises the dehydrative cyclisaton of a compound of formula II. (II).
    Type: Grant
    Filed: March 25, 2005
    Date of Patent: October 21, 2008
    Assignee: AstraZeneca AB
    Inventor: John Pavey
  • Patent number: 7439240
    Abstract: The present invention therefore provides a compound of formula (I) and compositions for treating diseases associated with cysteine protease activity. The compounds are reversible inhibitors of cysteine proteases S, K, F, L and B. Of particular interest are diseases associated with Cathepsin S. In addition this invention also discloses processes for the preparation of such inhibitors.
    Type: Grant
    Filed: June 23, 2003
    Date of Patent: October 21, 2008
    Assignee: AstraZeneca AB
    Inventors: Andrew Bailey, Garry Pairaudeau, Anil Patel, Stephen Thom
  • Publication number: 20080255106
    Abstract: Compounds of formula I wherein R1, R2, R3, R4, R5, R6 and R7 are as defined in the specification, as a base or a pharmaceutically acceptable salt, solvate or solvate of salt thereof, processes for their preparation and new intermediates used therein, pharmaceutical formulations containing said compounds and to the use of said compounds in therapy.
    Type: Application
    Filed: October 2, 2006
    Publication date: October 16, 2008
    Applicant: AstraZeneca AB
    Inventors: Per I. Arvidsson, Erwan Arzel, Jeremy Burrows, Helena Gyback, Tobias Rein, Didier Rotticci, Peter Soderman
  • Publication number: 20080255183
    Abstract: The present invention relates to compounds that inhibit of a5b1 function, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment in warm-blooded animals such as humans of diseases that have a significant angiogenesis or vascular component such as for treatment of solid tumours. The present invention also relates to a5b1 antagonists that also exhibit appropriate selectivity profile(s) against other integrins.
    Type: Application
    Filed: April 11, 2008
    Publication date: October 16, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Jean-Claude ARNOULD, Benedicte DELOUVRIE, Craig Steven HARRIS
  • Publication number: 20080255150
    Abstract: The invention relates to substituted aryl acids as useful pharmaceutical compounds for treating respiratory disorders, pharmaceutical compositions containing them, and processes for their preparation.
    Type: Application
    Filed: November 1, 2006
    Publication date: October 16, 2008
    Applicant: ASTRAZENECA AB
    Inventor: Timothy Luker
  • Publication number: 20080255207
    Abstract: The present invention relates to certain novel compounds of the Formula (I) to processes for preparing such compounds, to their the utility in modulation of nuclear hormone receptors Liver X Receptor (LXR) ?(NR1H3) and/or ?(NR1H2) and in treating clinical conditions including cardiovascular diseases such as atherosclerosis; inflammatory diseases, Alzheimer's disease, lipid disorders (dyslipidemias) whether or not associated with insulin resistance, type 2 diabetes and other manifestations of the metabolic syndrome, to methods for their therapeutic use and to pharmaceutical compositions containing them.
    Type: Application
    Filed: January 9, 2006
    Publication date: October 16, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Patrik Holm, Lanna Li
  • Publication number: 20080255122
    Abstract: The present invention relates to certain novel compounds of the formula (I) to processes for preparing such compounds, to their the utility in modulation of nuclear hormone receptors Liver X Receptor (LXR) ? (NR1H3) and/or ? (NR1H2) and in treating and/or preventing clinical conditions including cardiovascular diseases such as atherosclerosis; inflammatory diseases, Alzheimer's disease, lipid disorders (dyslipidemias) whether or not associated with insulin resistance, type 2 diabetes and other manifestations of the metabolic syndrome, to methods for their therapeutic use and to pharmaceutical compositions containing them.
    Type: Application
    Filed: January 9, 2006
    Publication date: October 16, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Jonas Bostrom, Kay Brickmann, Anders Broo, Robert Judkins, Lanna Li, Pernilla Sandberg, Marianne Swanson, Christer Westerlund, Patrik Holm